Test First Demo Article


Share / Export Citation / Email / Print / Text size:

Test Demo Journal

Medical Communications

Subject: Acoustics


ISSN: 1234-5678
eISSN: 8759-3456






Volume / Issue / page

Volume 1 (2001)
Related articles

VOLUME 1 , ISSUE 1 (January 2001) > List of articles

  • |

Test First Demo Article

tarun managal

Keywords : neuronal impairment, sodium deoxycholate, cholic acid, amyloid plaque deposit, hippocampus, acetylcholinesterase

shivani : 12

Citation Information : Test Demo Journal. Volume 1, Issue 1, Pages 1,234-12,345, DOI: https://doi.org/10.1515/demoarticle-2020-2010

License : (CC BY-SA 4.0)

Received Date : 31-August-2020 / Accepted: 01-September-2020 / Published Online: 02-September-2020

Open Access article funded by Tarun



Acetylcholine is a fast-acting neurotransmitter in synapses and neuromuscular junctions that is decreased in Alzheimer’s disease (AD) by hyper-activation of acetylcholinesterase (AChE), which leads to progressive loss of memory and neurobehavioral abnormalities. Therefore, AChE inhibitors have therapeutic potential in AD that could include natural compounds such as bile acids. Bile acids, as potent molecules, could improve some types of neurodegenerative diseases via antioxidant effects and other unknown mechanisms. The aim of this study was to investigate beneficial effects of bile acids on AChE catalytic and non-catalytic functions, amyloid plaque deposit and memory in a rat model of AD. The effects of sodium deoxycholate and cholic acid on AChE activity were assessed by in vitro assay. Then, the bile acids’ potential therapeutic effects were investigated on nucleus basalis of Meynert lesioned rats using behavioral evaluation, biochemical tests and histological methods. Molecular docking simulation was also implemented to investigate the possible interaction between bile acids and AChE. According to the in vitro and in vivo results, sodium deoxycholate could efficiently inhibit the catalytic function of the enzyme by interacting with the catalytic site, while cholic acid interacted with the peripheral anionic site and inhibited chaperone activity of the enzyme that led to the reduced amyloid plaque deposition. The co-administration of cholic acid and sodium deoxycholate showed these compounds are able to simultaneously inhibit the catalytic and non-catalytic functions of the enzyme. This study clarifies the roles of natural bile acids in the nervous system and in AChE function through multiple experimental and simulation methods.

Content not available PDF Share



1. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW (2003) Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta 1637: 142–150.

2. Ackerman HD, Gerhard GS (2016) Bile acids in neurodegenerative disorders. Front Aging Neurosci 8: 263.

3. Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 36: 375–399.

4. Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G (2008) DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson’s disease and involvement of HSP70. PLoS One 3: e1884.

5. Bradford MM (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.

6. Dong H, Xiang YY, Farchi N, Ju W, Wu Y, Chen L, Wang Y, Hochner B, Yang B, Soreq H, Lu WY (2004) Excessive expression of acetylcholinesterase impairs glutamatergic synaptogenesis in hippocampal neurons. J Neurosci 24: 8950–8960.

7. Dong S, Duan Y, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 1: 18.

8. García-Ayllón MS, Small DH, Avila J, Sáez-Valero J (2011) Revisiting the role of acetylcholinesterase in alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front Mol Neurosci 4: 22.

9. Gratwicke J, Kahan J, Zrinzo L, Hariz M, Limousin P, Foltynie T, Jahanshahi M (2013) The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev 37: 2676–2688.

10. Holmquist M (2000) Alpha/Beta hydrolase fold enzymes: structures, functions and mechanisms. Curr Protein Pept Sci 1: 209–235.

11. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16: 881–891.

12. Johnson G, Moore SW (2006) The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. Curr Pharm 12: 217–225.

13. Lei J, Gao G, Feng J, Jin Y, Wang C, Mao Q, Jiang J (2015) Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study. Crit Care 19: 362.

14. Liu Y, Yan B, Winkler DA, Fu J, Zhang A (2017) Competitive inhibition mechanism of acetylcholinesterase without catalytic active site interaction: study on functionalized C60 nanoparticles via in vitro and in silico assays. ACS Appl Mater Interfaces 9: 18626–18638.

15. Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CM, D’Hooge R (2013) Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis 50: 21–29.

16. Mertens KL, Kalsbeek A, Soeters MR, Eggink HM (2017) Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci 11: 617.

17. Moodley K, Minati L, Contarino V, Prioni S, Wood R, Cooper R, D’Incerti L, Tagliavini F, Chan D (2015) Diagnostic differentiation of mild cognitive impairment due to Alzheimer’s disease using a hippocampus-dependent test of spatial memory. Hippocampus 25: 939–951.

18. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785–2791.

19. Pan X, Elliott CT, McGuinness B, Passmore P, Kehoe PG, Hölscher C, McClean PL, Graham SF, Green BD (2017) Metabolomic profiling of bile acids in clinical and experimental samples of Alzheimer’s disease. Metabolites 7: E28.

20. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. 15th ed. Academic Press, San Diego.

21. Prasher VP (2004) Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry 19: 509–515.

22. Rizvi SMD, Shakil S, Haneef M (2013) A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J 12: 831–857.

23. Sadeghi L, Rizvanov AA, Salafutdinov II, Dabirmanesh B, Sayyah M, Fathollahi Y (2017) Hippocampal asymmetry: differences in the left and right hippocampus proteome in the rat model of temporal lobe epilepsy. J Proteomics 154: 22–29.

24. Sadeghi L, Yousefi Babadi V, Tanwir F (2018) Improving effects of Echium amoenum aqueous extract on rat model of Alzheimer’s disease. J Integr Neurosci 17: 661–669.

25. Seibenhener ML, Wooten MW (2012) Isolation and culture of hippocampal neurons from prenatal mice. J Vis Exp 65: 1–6.

26. Toledano A, Alvarez MI (2004) Lesions and dysfunctions of the nucleus basalis as Alzheimer’s disease models: general and critical overview and analysis of the long-term changes in several excitotoxic models. Curr Alzheimer Res 1: 189–214.

27. Viana RJ, Ramalho RM, Nunes AF, Steer CJ, Rodrigues CM (2010) Modulation of amyloid-beta peptide-induced toxicity through inhibition of JNK nuclear localization and caspase-2 activation. J Alzheimers Dis 22: 557–568.

28. Wenk GL (1990) Animal models of Alzheimer’s disease: are they valid and useful? Acta Neurobiol E



  • |